Oncology Drug Reference Sheet: Elranatamab-Bcmm

Elranatamab-bcmm, an immunotherapy indicated for relapsed or refractory multiple myeloma, received accelerated approval in 2023. It is a bispecific antibody and T-cell engager that binds to BCMA, which occurs on the surface of myeloma and other cells, and CD3, which occurs on T cells, causing cytokine release and myeloma cell lysis. This ONS resource was produced for educational purposes only. Refer to the full elranatamab-bcmm (Elrexfio^™) package insert for all details.